UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
March 15, 2018
Date of Report (Date of Earliest Event Reported)
The Chemours Company
(Exact Name of Registrant as Specified in Its Charter)
|
|
||||
|
|
|
|
|
|
|
Delaware |
|
001-36794 |
|
46-4845564 |
|
(State or Other Jurisdiction |
|
(Commission |
|
(I.R.S. Employer |
|
Of Incorporation) |
|
File Number) |
|
Identification No.) |
1007 Market Street
Wilmington, Delaware, 19899
(Address of principal executive offices)
Registrant’s telephone number, including area code: (302) 773-1000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
|
Emerging growth company |
|
☐ |
|
|
|
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. |
|
☐ |
|
|
|
|
The Chemours Company (“Chemours” or the “Company”) today reported that Mark P. Vergnano, President and Chief Executive Officer, entered into a trading plan (the “Plan”) in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Plan, executed during the Company’s open trading window, is set to be in effect from May 8, 2018 to December 1, 2020 to facilitate the exercise of 574,302 expiring options, and to sell the underlying shares. These expiring stock options were issued to Mr. Vergnano while he was with E. I. du Pont de Nemours and Company (“DuPont”) and were converted to Chemours options in connection with the Company’s separation from DuPont. Mr. Vergnano entered into the Plan to allow for an orderly exercise of the options prior to their expiration as part of his personal long-term financial planning. Any transactions under the Plan will be publicly reported through Form 4 filings with the Securities and Exchange Commission.
Other officers of the Company may have entered into Rule 10b5-1 trading plans related to the Company’s shares and may enter into such plans in the future. The Company undertakes no obligation to report Rule 10b5-1 trading plans adopted by any of its officers or directors, or to report any modifications or terminations of any publicly announced plans, except to the extent required by law.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
THE CHEMOURS COMPANY |
||
|
|
||
|
By: |
|
/s/ Mark E. Newman |
|
|
|
Mark E. Newman |
|
|
|
Senior Vice President and |
|
|
|
Chief Financial Officer |
|
|
||
|
Date: |
|
March 15, 2018 |